What are the treatment options for a patient with psoriasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Psoriasis

For mild psoriasis (<5% body surface area), initiate treatment with high-potency topical corticosteroids (class 2-5) combined with calcipotriene for 2-4 weeks, achieving 58-92% clearance rates. 1, 2


Topical Therapy for Mild Disease

First-line combination therapy is the most effective approach for localized psoriasis:

  • Apply high-potency topical corticosteroids (clobetasol propionate 0.05% or betamethasone dipropionate 0.05%) twice daily for maximum 2-4 weeks, combined with calcipotriene for synergistic effect 1, 2
  • Use low-potency corticosteroids or topical calcineurin inhibitors (tacrolimus 0.1%) on the face, genitals, and intertriginous areas to avoid skin atrophy 1, 3
  • For scalp involvement, use topical corticosteroids (class 1-7) for at least 4 weeks 1

Maintenance regimen after initial clearance:

  • Apply corticosteroids on weekends only while using vitamin D analogs (calcipotriene) on weekdays to prevent tachyphylaxis 1
  • Limit moderate-potency corticosteroid use to maximum 100g per month 1, 3

Alternative topical agents when first-line fails:

  • Add tazarotene (topical retinoid) to moderate-to-high potency corticosteroids to reduce irritation while enhancing efficacy 1, 3
  • Start coal tar at 0.5-1.0% concentration and increase gradually to maximum 10% 1, 3

Systemic Therapy for Moderate-to-Severe Disease

Escalate to systemic therapy when body surface area exceeds 5%, or when topical therapy fails after 8 weeks, or when psoriasis affects quality of life despite limited body surface involvement. 4, 3

Phototherapy as First-Line Systemic Treatment

  • Photochemotherapy (PUVA) is the least toxic systemic agent and should be considered first-line systemic treatment, starting at 70% of minimum phototoxic dose and increasing successive doses by 40% if no erythema develops 2, 3
  • Narrowband UVB phototherapy is first-line for pregnant women with moderate to severe psoriasis, as it lacks systemic toxicities 2

Conventional Systemic Agents

When phototherapy is inadequate or unavailable:

  • Methotrexate is especially useful in acute generalized pustular psoriasis, psoriatic erythroderma, psoriatic arthritis, and extensive chronic plaque psoriasis, with response time of 2 weeks 2, 3

    • Absolute contraindications include pregnancy, breastfeeding, wish to father children, significant hepatic damage, anemia, leucopenia, thrombocytopenia 3
  • Cyclosporine is first-line for erythrodermic psoriasis, with dramatic improvement during 2-3 weeks 2

  • Acitretin has response time of 2-6 weeks but is contraindicated in pregnancy 3


Biologic Therapy

For moderate-to-severe psoriasis when conventional systemic agents are contraindicated or ineffective:

  • Biologics (adalimumab, infliximab, ustekinumab, etanercept) achieve treatment goals in 68.2-79.3% of patients by week 16 2, 3
  • Infliximab demonstrates rapid and often complete disease clearance for generalized pustular psoriasis and should be considered first-line biologic therapy, with standard dosing of 5 mg/kg infused at weeks 0,2, and 6, then every 8 weeks thereafter 2, 3
  • Adalimumab dosing for plaque psoriasis: 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose 5
  • Screen for active or latent tuberculosis, hepatitis B, and fungal infections before initiating biologics 3, 5

Critical Medications to Absolutely Avoid

NEVER prescribe systemic corticosteroids for psoriasis—they precipitate erythrodermic psoriasis, generalized pustular psoriasis, or very unstable disease upon discontinuation. 1, 2, 3

Other medications that cause severe, potentially fatal psoriasis deterioration:

  • Lithium, chloroquine, and mepacrine are absolutely contraindicated 1, 2, 3
  • Beta-blockers and non-steroidal anti-inflammatory drugs can worsen psoriasis in some patients 1
  • Avoid simultaneous use of salicylic acid with calcipotriol, as the acidic pH inactivates calcipotriol 1

Common Pitfalls and How to Avoid Them

  • Perceived "tachyphylaxis" to topical corticosteroids is usually due to poor patient adherence rather than true receptor down-regulation—address compliance issues before switching therapies 1, 3
  • Patients who fail to respond to one topical agent may respond to another for unclear reasons—trial alternative topical agents before escalating to systemic therapy 1, 3
  • Avoid prescribing refills without medical supervision and ensure regular clinical follow-up when using topical corticosteroids 1
  • Plan annual periods where alternative treatments are employed to prevent long-term complications 1, 3

Referral to Dermatology

  • Most patients with chronic stable plaque psoriasis can be managed in primary care 1
  • Refer patients requiring systemic agents to a dermatologist due to potential toxicity and need for specialized monitoring 4, 1
  • Refer patients with psoriatic arthritis, erythrodermic psoriasis, or generalized pustular psoriasis for specialist management 4, 2

References

Guideline

Management of Psoriasis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Psoriasis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Psoriasis Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.